Understanding disease mechanisms in ALS and frontotemporal dementia
Official title: Integrating Spatial Multi-omics and Clinical Covariates to Identify Mechanisms of Disease in ALS-FTD
Funded at New York Genome Center · NIH-10824396 · Data updated 2026-11-12
This study is looking at brain tissue from people who had ALS and frontotemporal dementia to understand how changes in brain cells affect the symptoms they experienced, with the hope of finding new ways to diagnose and treat these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Genome Center NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $751,277 |
| NIH project number | 5R01NS118183-05 |
| Project ID | NIH-10824396 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with ALS or FTD, particularly those exhibiting cognitive deficits.
✕Less likely to help
Patients with other neurological disorders unrelated to ALS or FTD may not receive any benefit from this research.
What this research studies
This research investigates the underlying mechanisms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) by analyzing post-mortem brain tissue. The study aims to identify how different cellular interactions and molecular changes contribute to the cognitive and motor symptoms experienced by patients. By employing advanced multi-omic techniques, researchers will explore the relationship between TDP-43 pathology and cognitive deficits, potentially uncovering new biomarkers for these conditions. Patients may benefit from insights that could lead to improved diagnostic and therapeutic strategies.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of ALS and FTD, potentially improving patient outcomes.
How similar studies have gone: Previous research has shown promise in understanding ALS and FTD through similar multi-omic approaches, indicating potential for success in this study.
Where this research is happening
-
New York Genome Center
New York, United States Active
Researchers
- Principal investigator: Phatnani, Hemali — New York Genome Center
- Study coordinator: Phatnani, Hemali
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.